What is Chardan Capital's Forecast for SLDB FY2025 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Chardan Capital lifted their FY2025 earnings estimates for Solid Biosciences in a report issued on Wednesday, February 19th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($1.82) for the year, up from their prior forecast of ($2.03). Chardan Capital has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

A number of other analysts have also recently weighed in on SLDB. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research report on Friday, January 10th. JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. Truist Financial started coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They set a "buy" rating and a $16.00 price target for the company. Citizens Jmp upgraded shares of Solid Biosciences to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, JMP Securities assumed coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective for the company. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Solid Biosciences has a consensus rating of "Buy" and a consensus price target of $15.40.

Remove Ads

Solid Biosciences Price Performance

Shares of SLDB traded up $0.04 during mid-day trading on Monday, reaching $5.33. The company had a trading volume of 1,084,148 shares, compared to its average volume of 3,205,798. The company has a market capitalization of $216.29 million, a P/E ratio of -1.75 and a beta of 2.01. Solid Biosciences has a twelve month low of $2.88 and a twelve month high of $15.05. The company's 50-day moving average is $3.89 and its 200-day moving average is $5.71.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP boosted its stake in Solid Biosciences by 1.8% during the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock worth $11,400,000 after acquiring an additional 50,000 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Solid Biosciences by 9,393.8% during the fourth quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after purchasing an additional 945,863 shares in the last quarter. Redmile Group LLC bought a new position in shares of Solid Biosciences during the fourth quarter worth $2,461,000. Geode Capital Management LLC grew its holdings in shares of Solid Biosciences by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 509,802 shares of the company's stock valued at $2,040,000 after buying an additional 4,932 shares during the period. Finally, Point72 Asset Management L.P. increased its position in shares of Solid Biosciences by 292.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company's stock valued at $3,088,000 after buying an additional 330,234 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Alexander Cumbo sold 11,114 shares of the firm's stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $62,238.40. Following the transaction, the chief executive officer now directly owns 38,484 shares in the company, valued at $215,510.40. This trade represents a 22.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jessie Hanrahan sold 4,610 shares of the company's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares of the company's stock, valued at $79,716. This represents a 24.46 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,069 shares of company stock valued at $137,301. 13.63% of the stock is currently owned by insiders.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.